ArticleBMC medicine2024
Changes in sarcopenia and incident cardiovascular disease in prospective cohorts.
Article in BMC medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The association of multi-system health status and its longitudinal changes with cardiovascular disease risk: insights from a secondary analysis of four multinational cohort studies.Journal of global health · 2026Article
- Interrelationship Between Sarcopenia, Frailty and Cardiovascular Disease-The Crucial Role of Obesity in Hypothesis Generation-A Narrative Review.Journal of personalized medicine · 2026Review
- Nutrition impact symptoms and the risk of malnutrition, frailty, and sarcopenia in adults with cancer: A cross-sectional latent class analysis.JPEN. Journal of parenteral and enteral nutrition · 2026Article
- Construction and validation of a machine learning model to predict the sarcopenic obesity population.Medicine · 2026Article
- Association of longitudinal changes in depressive symptoms and handgrip strength with cardiovascular disease in middle-aged and elderly populations.BMC public health · 2026Article
- Sarcopenia changes and incident type 2 diabetes mellitus: a prospective analysis of the CHARLS cohort.BMC geriatrics · 2026Article
- Associations of Baseline and Changes in Intrinsic Capacity With Incident Cardiovascular Disease: A Multicohort Study.Journal of the American Heart Association · 2026Article
- Mechanisms Linking Oxidative Stress and Sarcopenia in Cardiovascular Diseases: A Scoping Review.Antioxidants (Basel, Switzerland) · 2026Review
- Prediction Model for Frailty in Middle-Aged and Older Adults with Cardiovascular Disease.Vascular health and risk management · 2026Article
- Transitions in Sarcopenia Status and Cognitive Trajectories Among Middle-Aged and Older Adults in China: Longitudinal Cohort Study.JMIR aging · 2025Article
- Sarcopenia risk along the cardiovascular-kidney-metabolic syndrome spectrum: synergistic effects of multisystem burden and physical inactivity.BMC public health · 2025Article
- Network pharmacology analysis and in vitro verification of the anti-sarcopenia effects of formononetin.Bioresources and bioprocessing · 2025Article
- Combined and progressive effect of frailty and sarcopenia on the risk of cardiovascular disease in middle-aged and older adults.Journal of global health · 2025Article
- Article
- Association of combined left and right handgrip strength with new-onset chronic kidney disease in middle-aged and older adults: a nationwide multicenter cohort study.BMC public health · 2025Observational
- Association between the triglyceride-glucose-waist-to-height ratio and cardiovascular disease in Chinese adults with sarcopenia or probable sarcopenia.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have identified sarcopenia as a significant risk factor for cardiovascular disease (CVD). However, these studies primarily focused on sarcopenia status at baseline, without considering changes in sarcopenia status during follow-up. The aim of this study is to investigate the association between changes in sarcopenia status and the incidence of new-onset cardiovascular disease.
methodsThis study utilized prospective cohort data from the China Health and Retirement Longitudinal Study (CHARLS). Sarcopenia status was assessed using the 2019 Asian Working Group for Sarcopenia (AWGS) algorithm and categorized as non-sarcopenia, possible sarcopenia, or sarcopenia. Changes in sarcopenia status were evaluated based on assessments at baseline and at the second follow-up survey 2 years later. CVD was identified through self-reported physician diagnoses of heart disease, including angina, myocardial infarction, congestive heart failure, and other heart problems, or stroke. Cox proportional hazards models were employed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for potential confounding factors.
resultsBased on the inclusion and exclusion criteria, a total of 7499 CHARLS participants were included in the analysis, with 50.8% being female and an average age of 58.5 years. Compared to participants with stable non-sarcopenia status, those who progressed from non-sarcopenia to possible sarcopenia or sarcopenia exhibited a significantly increased risk of new-onset CVD (HR 1.30, 95% CI 1.06-1.59). Conversely, participants who recovered from sarcopenia to non-sarcopenia or possible sarcopenia had a significantly reduced risk of new-onset CVD compared to those with stable sarcopenia status (HR 0.61, 95% CI 0.37-0.99). Among participants with baseline possible sarcopenia, those who recovered to non-sarcopenia had a significantly lower risk of new-onset CVD compared to those with stable possible sarcopenia status (HR 0.67, 95% CI 0.52-0.86).
conclusionsChanges in sarcopenia status are associated with varying risks of new-onset CVD. Progression in sarcopenia status increases the risk, while recovery from sarcopenia reduces the risk of developing cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.